vs
Apellis Pharmaceuticals, Inc.（APLS）与MEDICAL PROPERTIES TRUST INC（MPW）财务数据对比。点击上方公司名可切换其他公司
MEDICAL PROPERTIES TRUST INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.4倍（$270.3M vs $199.9M），MEDICAL PROPERTIES TRUST INC净利率更高（6.5% vs -29.5%，领先36.0%），MEDICAL PROPERTIES TRUST INC同比增速更快（16.6% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -0.2%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Medical Properties Trust, Inc.（MPT）是一家总部位于美国阿拉巴马州伯明翰的跨国房地产投资信托基金（REIT），主要在美欧地区收购、投资医疗保健设施与营利性医疗控股公司，资产收购多采用售后回租模式，原业主出售资产后成为其租户，租户通常需签署长期三净租赁协议。
APLS vs MPW — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $270.3M |
| 净利润 | $-59.0M | $17.6M |
| 毛利率 | — | 95.8% |
| 营业利润率 | -25.6% | 9.7% |
| 净利率 | -29.5% | 6.5% |
| 营收同比 | -5.9% | 16.6% |
| 净利润同比 | -62.2% | 104.3% |
| 每股收益（稀释后） | $-0.40 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $270.3M | ||
| Q3 25 | $458.6M | $237.5M | ||
| Q2 25 | $178.5M | $240.4M | ||
| Q1 25 | $166.8M | $223.8M | ||
| Q4 24 | $212.5M | $231.8M | ||
| Q3 24 | $196.8M | $225.8M | ||
| Q2 24 | $199.7M | $266.6M | ||
| Q1 24 | $172.3M | $271.3M |
| Q4 25 | $-59.0M | $17.6M | ||
| Q3 25 | $215.7M | $-77.7M | ||
| Q2 25 | $-42.2M | $-98.4M | ||
| Q1 25 | $-92.2M | $-118.3M | ||
| Q4 24 | $-36.4M | $-412.3M | ||
| Q3 24 | $-57.4M | $-801.2M | ||
| Q2 24 | $-37.7M | $-320.6M | ||
| Q1 24 | $-66.4M | $-875.6M |
| Q4 25 | — | 95.8% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 91.8% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 96.5% | ||
| Q2 24 | — | 98.4% | ||
| Q1 24 | — | 84.9% |
| Q4 25 | -25.6% | 9.7% | ||
| Q3 25 | 48.7% | -28.0% | ||
| Q2 25 | -18.6% | -36.7% | ||
| Q1 25 | -50.0% | -48.5% | ||
| Q4 24 | -12.3% | -173.7% | ||
| Q3 24 | -24.0% | -350.7% | ||
| Q2 24 | -14.7% | -114.5% | ||
| Q1 24 | -36.0% | -318.6% |
| Q4 25 | -29.5% | 6.5% | ||
| Q3 25 | 47.0% | -32.7% | ||
| Q2 25 | -23.6% | -40.9% | ||
| Q1 25 | -55.3% | -52.8% | ||
| Q4 24 | -17.1% | -177.8% | ||
| Q3 24 | -29.2% | -354.8% | ||
| Q2 24 | -18.9% | -120.3% | ||
| Q1 24 | -38.5% | -322.7% |
| Q4 25 | $-0.40 | $0.03 | ||
| Q3 25 | $1.67 | $-0.13 | ||
| Q2 25 | $-0.33 | $-0.16 | ||
| Q1 25 | $-0.74 | $-0.20 | ||
| Q4 24 | $-0.30 | $-0.68 | ||
| Q3 24 | $-0.46 | $-1.34 | ||
| Q2 24 | $-0.30 | $-0.54 | ||
| Q1 24 | $-0.54 | $-1.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $540.9M |
| 总债务越低越好 | — | $9.7B |
| 股东权益账面价值 | $370.1M | $4.6B |
| 总资产 | $1.1B | $15.0B |
| 负债/权益比越低杠杆越低 | — | 2.11× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $540.9M | ||
| Q3 25 | $479.2M | $396.6M | ||
| Q2 25 | $370.0M | $509.8M | ||
| Q1 25 | $358.4M | $673.5M | ||
| Q4 24 | $411.3M | $332.3M | ||
| Q3 24 | $396.9M | $275.6M | ||
| Q2 24 | $360.1M | $606.5M | ||
| Q1 24 | $325.9M | $224.3M |
| Q4 25 | — | $9.7B | ||
| Q3 25 | — | $9.6B | ||
| Q2 25 | — | $9.6B | ||
| Q1 25 | — | $9.5B | ||
| Q4 24 | — | $8.8B | ||
| Q3 24 | — | $9.2B | ||
| Q2 24 | — | $9.4B | ||
| Q1 24 | $93.1M | $10.1B |
| Q4 25 | $370.1M | $4.6B | ||
| Q3 25 | $401.2M | $4.7B | ||
| Q2 25 | $156.3M | $4.8B | ||
| Q1 25 | $164.2M | $4.8B | ||
| Q4 24 | $228.5M | $4.8B | ||
| Q3 24 | $237.1M | $5.4B | ||
| Q2 24 | $264.3M | $6.2B | ||
| Q1 24 | $266.7M | $6.7B |
| Q4 25 | $1.1B | $15.0B | ||
| Q3 25 | $1.1B | $14.9B | ||
| Q2 25 | $821.4M | $15.2B | ||
| Q1 25 | $807.3M | $14.9B | ||
| Q4 24 | $885.1M | $14.3B | ||
| Q3 24 | $901.9M | $15.2B | ||
| Q2 24 | $904.5M | $16.2B | ||
| Q1 24 | $831.9M | $17.3B |
| Q4 25 | — | 2.11× | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | — | 2.00× | ||
| Q1 25 | — | 1.99× | ||
| Q4 24 | — | 1.83× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.51× | ||
| Q1 24 | 0.35× | 1.51× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $230.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 13.11× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $230.8M | ||
| Q3 25 | $108.5M | $18.6M | ||
| Q2 25 | $4.4M | $51.7M | ||
| Q1 25 | $-53.4M | $384.0K | ||
| Q4 24 | $19.4M | $245.5M | ||
| Q3 24 | $34.1M | $59.2M | ||
| Q2 24 | $-8.3M | $35.3M | ||
| Q1 24 | $-133.0M | $74.3M |
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | — | 13.11× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
MPW
暂无分部数据
